Michael Forbes

Canadian Marijuana Stock Posts 133% YoY Revenue Growth, But Also 124% Higher Net Loss In Q2

Canadian Weed Company Adastra Reports Triple-Digit Q1 Revenue Growth, What's Behind The Figures?

Adastra FY22 Revenue Grows 136%, Here Is What You Need To Know

Canadian Weed Company Adastra Reports Triple-Digit Q1 Revenue Growth, What's Behind The Figures?

Adastra FY22 Revenue Grows 136%, Here Is What You Need To Know

Adastra Stock Skyrockets On Record Shipment Volume, Following The News Of Civil Lawsuit

Canadian Weed Company's Plan To Produce Cocaine Shocks Local Leader, Opposition Questions Drug Experiment

Adastra Stock Skyrockets On Record Shipment Volume, Following The News Of Civil Lawsuit

Canadian Weed Company's Plan To Produce Cocaine Shocks Local Leader, Opposition Questions Drug Experiment

Canada Gives This Cannabis Company The Green Light To Handle Cocaine, Psilocybin

Key Marijuana Executive Changes You Should Know About: New Appointments & More

Michael Forbes Recent News

Adastra Q3 Revenue Grows 110% YoY To $2.83M

Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX)(FRA:D2EP), released its financial results for the three and nine months ended September 30, 2022. Q3 2022 Financial Highlights

Cannabis Movers & Shakers: OnPoint Laboratories, Neptune Wellness, Adastra Holdings & Cannaverse Technologies

OnPoint Laboratories Names Samuel Richard CEO & Equity Partner OnPoint Laboratories has appointed Samuel Richard to serve as CEO and equity partner. Richard succeeds Jeff Cardot, founder and current CEO, as part of a planned transition.

Adastra Holdings Reports Record Revenue In 2021, Here Are The Details

Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) has filed its consolidated financial statements and related management discussion and analysis for the year ended December 31, 2021.

Adastra Submits Medical Sales License Application And Engages IR Labs To Provide Investor Relations Services

Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) submitted medical sales license application to Health Canada on April 1, 2022. A medical sales license would permit Adastra to perform the following activities:

Adastra Holdings Approved For Dealer's License For Psilocybin, Psilocin, MDMA, DMT, 5-MeO-DMT & LSD

Adastra Holdings Ltd. (OTCPK: XTXXF) (CSE: XTRX) (FRA: D2EP) recently completed the submission of its application for a controlled drugs and substances dealer's license. What Does It Mean?

Adastra Holdings To Bring Zyre Brands Cannabis Vapes To Canadian Market

Adastra Holdings Ltd. (CSE:XTRX) (FRANKFURT:D2EP) entered into a private label manufacturing agreement with Zyre Brands Corp. under which Adastra will manufacture custom-formulated cured resin vape products to sell under the Zyre brand in the Canadian adult-use market.